U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C35H53NO3
Molecular Weight 535.8002
Optical Activity ( + / - )
Defined Stereocenters 3 / 3
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of .ALPHA.-TOCOPHEROL NICOTINATE, DL-

SMILES

CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@]1(C)CCC2=C(O1)C(C)=C(C)C(OC(=O)C3=CN=CC=C3)=C2C

InChI

InChIKey=MSCCTZZBYHQMQJ-AZAGJHQNSA-N
InChI=1S/C35H53NO3/c1-24(2)13-9-14-25(3)15-10-16-26(4)17-11-20-35(8)21-19-31-29(7)32(27(5)28(6)33(31)39-35)38-34(37)30-18-12-22-36-23-30/h12,18,22-26H,9-11,13-17,19-21H2,1-8H3/t25-,26-,35-/m1/s1

HIDE SMILES / InChI

Description
Curator's Comment: Description was created based on several sources, including https://www.springboard4health.com/notebook/v_e.html and http://www.ncbi.nlm.nih.gov/pubmed/2134664

Tocopherol (alpha tocopheryl nicotinate) is an ester of tocopherol and nicotinic acid. Vitamin E (Tocopherol) is sold commercially as the esterified form (alpha tocopheryl acetate, alpha tocopheryl succinate and alpha tocopheryl nicotinate). Alpha tocopheryl nicotinate has antioxidant and vasodilatory properties. It can be used as a mild warming agent, without producing the redness typical for nicotinic acid. Tocopherol (alpha tocopheryl nicotinate) has been available in Japan since 1967. Tocopherol under the brand name Juvela N is approved in Japan for the treatment of symptoms accompanying hypertension, hyperlipidemia, peripheral circulatory disturbance resulting from arteriosclerosis obliterans. Tocopherol has being shown to inhibit platelet aggregation.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Juvela N

Approved Use

Accompanying symptoms resulting from the following Hypertension Hyperlipidemia Peripheral circulatory disturbance resulting from the following Arteriosclerosis obliterans

Launch Date

1966
Primary
Juvela N

Approved Use

Accompanying symptoms resulting from the following Hypertension Hyperlipidemia Peripheral circulatory disturbance resulting from the following Arteriosclerosis obliterans

Launch Date

1966
Primary
Juvela N

Approved Use

Accompanying symptoms resulting from the following Hypertension Hyperlipidemia Peripheral circulatory disturbance resulting from the following Arteriosclerosis obliterans

Launch Date

1966
PubMed

PubMed

TitleDatePubMed
A family of familial hypercholesterolemia with cerebral infarction and without coronary heart disease. An unusual case with corneal opacity, polyneuropathy and carpal tunnel syndrome in the family: therapy with probucol and tocopherol nicotinate.
1991 Nov
Final report on the safety assessment of Tocopherol, Tocopheryl Acetate, Tocopheryl Linoleate, Tocopheryl Linoleate/Oleate, Tocopheryl Nicotinate, Tocopheryl Succinate, Dioleyl Tocopheryl Methylsilanol, Potassium Ascorbyl Tocopheryl Phosphate, and Tocophersolan.
2002
UPLC method for the determination of vitamin E homologues and derivatives in vegetable oils, margarines and supplement capsules using pentafluorophenyl column.
2014 Dec
Patents

Sample Use Guides

The usual adult dosage for oral use is 300 - 600 mg of tocopherol nicotinate (3 - 6 capsules) daily in three divided doses
Route of Administration: Oral
In Vitro Use Guide
177 uM of Tocopherol led to decreased human platelet aggregation in response to the combined ADP and H2O 2
Name Type Language
.ALPHA.-TOCOPHEROL NICOTINATE, DL-
Common Name English
J299.341D
Code English
TOCOPHEROL NICOTINATE [JAN]
Common Name English
TOCOPHERYL NICOTINATE, DL-.ALPHA.-
Common Name English
3-PYRIDINECARBOXYLIC ACID, 3,4-DIHYDRO-2,5,7,8-TETRAMETHYL-2-(4,8,12-TRIMETHYLTRIDECYL)-2H-1-BENZOPYRAN-6-YL ESTER, (2R*(4R*,8R*))-(±)-
Common Name English
TOCOPHEROL NICOTINATE
JAN  
Common Name English
JUVELA NICOTINATE
Brand Name English
DL-.ALPHA.-TOCOPHEROL NICOTINIC ACID ESTER
Common Name English
DL-.ALPHA.-TOCOPHERYL NICOTINATE
Common Name English
Code System Code Type Description
CAS
51898-34-1
Created by admin on Fri Dec 15 19:53:21 GMT 2023 , Edited by admin on Fri Dec 15 19:53:21 GMT 2023
PRIMARY
PUBCHEM
27990
Created by admin on Fri Dec 15 19:53:21 GMT 2023 , Edited by admin on Fri Dec 15 19:53:21 GMT 2023
PRIMARY
FDA UNII
QCP2FMP7I8
Created by admin on Fri Dec 15 19:53:21 GMT 2023 , Edited by admin on Fri Dec 15 19:53:21 GMT 2023
PRIMARY
EPA CompTox
DTXSID401019802
Created by admin on Fri Dec 15 19:53:21 GMT 2023 , Edited by admin on Fri Dec 15 19:53:21 GMT 2023
PRIMARY
ECHA (EC/EINECS)
257-501-4
Created by admin on Fri Dec 15 19:53:21 GMT 2023 , Edited by admin on Fri Dec 15 19:53:21 GMT 2023
PRIMARY
EVMPD
SUB15586MIG
Created by admin on Fri Dec 15 19:53:21 GMT 2023 , Edited by admin on Fri Dec 15 19:53:21 GMT 2023
PRIMARY